Some patients with large vessel occlusion strokes may still benefit from thrombolysis even after the traditional 4.5-hour window, new analysis of the TIMELESS trial suggested.
Global Venous Thromboembolism Market Forecast 2024-2033 – Market Size, Drivers, Trends, And Competitors einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
This result, along with its ease of use, adds to the growing evidence that tenecteplase should be a first-line thrombolytic agent, trial investigators say.
Tenecteplase confers similar reperfusion, safety, and functional outcomes as alteplase in patients with large-vessel occlusion stroke, new research shows.